Drugs in ATC Class J01MA

Up to Top Level ATC Classes

Up to J - Antiinfectives for systemic use

Up to J01 - ANTIBACTERIALS FOR SYSTEMIC USE

Up to J01M - QUINOLONE ANTIBACTERIALS

Drugs in ATC Class: J01MA - Fluoroquinolones

Tradename	Generic Name
TROVAN PRESERVATIVE FREE	alatrofloxacin mesylate
CILOXAN	ciprofloxacin hydrochloride
CIPROFLOXACIN HYDROCHLORIDE	ciprofloxacin hydrochloride
CETRAXAL	ciprofloxacin hydrochloride
PROQUIN XR	ciprofloxacin hydrochloride

Market dynamics and patent landscape for ATC Class J01MA (fluoroquinolones)

Last updated: June 11, 2026

Fluoroquinolones are a mature, heavily genericized antibiotic class in the US and EU. Most originator patent estates have expired, with the remaining value concentrated in (1) line-extensions protected by secondary IP (formulations, polymorphs, stereochemical variants, fixed-dose combinations, and method-of-use), (2) lifecycle IP around new delivery systems (long-acting injectables, inhaled options, and prodrug/active-ingredient refinements), and (3) product-specific exclusivities tied to new NDA/505(b)(2) approvals. Litigation is intermittent and usually product-specific rather than class-wide.

How many patents protect fluoroquinolones (J01MA) and who holds them?

No single “J01MA” patent estate exists. IP is held at the molecule and product level (for example, ciprofloxacin, levofloxacin, moxifloxacin, gatifloxacin, norfloxacin, ofloxacin, and older withdrawn members). For market dynamics and risk, the relevant question is not “how many fluoroquinolone patents exist,” but “which fluoroquinolone products still have enforceable secondary patents and what is their remaining term by jurisdiction.”

What patent types still matter in fluoroquinolones?

In a generic-dominated class, enforceable rights typically come from secondary patent families rather than core API synthesis/compound patents. Common remaining IP buckets include:

• Solid-state patents: polymorph/crystal form, hydrate/solvate, particle size distributions, and amorphous forms
• Formulation patents: film-coating, taste-masking, controlled release, sustained exposure, specific excipient systems
• Process patents: scalable manufacturing steps, impurity control, solvent systems, crystallization parameters
• Combination and dosing regimen patents: fixed-dose combinations, sequence-of-dosing claims, and method-of-use claims linked to narrower clinical subpopulations
• Device and delivery patents: inhaled formulations, ophthalmic delivery systems, otic delivery systems
• Regulatory-exclusivity linked to new indications: non-patent exclusivities can extend launch windows even after patent expiry, where applicable

Which companies still hold meaningful fluoroquinolone lifecycle IP?

As a practical matter, the firms most likely to maintain enforceable IP near-term are those that have conducted late lifecycle reformulations or have products approved via 505(b)(2) with exclusivity attached. Originators and their stewardship units, plus specialized generics that still secure and enforce formulation/process patents for branded generics, are the dominant holders. Because fluoroquinolone compound patents for major actives (ciprofloxacin, levofloxacin, moxifloxacin) are largely over, the remaining enforceable rights are concentrated in niche, product-specific families rather than across the whole ATC class.

When do major fluoroquinolone patents lose exclusivity in the US and EU?

Fluoroquinolone market access depends on three overlapping “time fences”:

1. US patent term (utility patents)
2. US regulatory exclusivity (new chemical entity, new therapeutic indication, pediatric exclusivity, orphan where relevant)
3. Market barriers created by Orange Book-listed exclusivities and listed patents tied to specific dosage forms/strengths

How do you model the launch calendar for fluoroquinolones?

A workable approach is to treat each relevant product as a separate economic unit:

• API-level patent expiry (often long past for mature fluoroquinolones)
• Secondary formulation/polymorph expiry
• Method-of-use expiry (if still listed)
• Regulatory exclusivity windows (can survive even when core compound patents expire)
• Settlement-triggered “carve-outs” in Paragraph IV cases

Key market reality for J01MA

For most widely used oral and IV fluoroquinolone products, the class is in a “generic first” regime in both the US and EU. Remaining exclusivity is typically shorter than investors expect, because late-stage reformulations and narrow indication patents create pockets of protection rather than a continuous class-wide moat.

What Orange Book status do fluoroquinolone products have (listed patents and exclusivities)?

Orange Book status is product and dosage-form specific. For fluoroquinolones, you generally see one of three profiles:

• Branded originator with limited remaining Orange Book listings (mainly secondary formulation patents)
• Branded generic or 505(b)(2) product with an exclusivity-lifecycle component and a smaller patent estate
• Fully generic environment where Orange Book listing counts are either zero (for non-branded products) or not tied to blockable patents

What patterns appear for fluoroquinolone Orange Book listings?

In a mature class, Orange Book listings that still matter tend to be:

• Crystallization/polymorph patents for API forms used in the NDA
• Controlled-release or extended exposure formulations (when applicable)
• Ophthalmic/otic formulations where delivery tech created separate patentable inventions
• Method-of-use claims linked to a labeled subgroup (less common than formulation patents in practice)

Which fluoroquinolone products face Paragraph IV challenges and settlements?

Paragraph IV filings drive market entry timing, but fluoroquinolones tend to have fewer ongoing “headline” Paragraph IV events than oncology or biologics. When litigation occurs, it is typically tied to:

• A remaining listed secondary patent (polymorph/formulation/process)
• A brand with a still-protected niche dosing form (for example, an extended-release tablet or a specialized ophthalmic/otic product)

What do fluoroquinolone settlements usually look like?

Settlement agreements in mature antibiotic classes are usually structured around:

• Design-around commitments (different polymorph/crystal form, altered formulation, different release profile)
• Launch-date entry with generic entry contingent on patent carve-outs
• Territory or strength limitations (generic launch in some strengths first)
• Omitted dosage forms where the listed patents cover specific strengths or release profiles

How strong is the patent estate for fluoroquinolones (J01MA) by mechanism?

Patent strength in fluoroquinolones is generally more fragile than in new therapeutic modalities because:

• The primary compound claims are historically older and often expired
• Most enforceable rights are secondary and vulnerable to design-arounds
• The space has a long record of generic manufacturing know-how and process adaptation

Where are the strongest pockets of protection?

The strongest enforceability tends to correlate with:

• Solid-state IP that ties to a specific API form used in the NDA
• Formulation IP that cannot be trivially replaced without altering performance or requiring a new regulatory package
• Method-of-use IP that is narrow and tied to an identified patient subset

Where are patents weakest?

Enforceability often weakens when claims cover:

• Broad method-of-use elements that overlap with standard of care
• Formulations where alternative excipient systems are routine and produce similar dissolution/exposure
• Process claims that can be avoided through alternate crystallization routes, impurity specs, or solvent systems

What formulations are protected for fluoroquinolones (extended release, polymorphs, and combinations)?

Secondary formulation IP is a key driver of remaining exclusivity and litigation risk.

Common formulation patent targets in J01MA

• Immediate-release tablet compositions that optimize dissolution and bioavailability
• Controlled-release and extended-release dosage forms
• Ophthalmic solutions/ointments with viscosity, pH, and preservative systems
• Otic drops for ear infection indications where vehicle and penetration matter
• Fixed-dose combinations (when present for specific marketed indications)
• API prodrug or stereochemical refinement where the labeled product uses a specific chemical identity

Why formulation patents matter for generics

Generics often cannot use a “different formulation with the same bioequivalence” without risking infringement if the Orange Book-listed formulation claims cover excipient systems or release mechanics. The design-around pathway depends on whether the active pharmaceutical ingredient form itself is implicated.

What manufacturing and IP barriers exist for generic fluoroquinolones?

Generic entry barriers are usually not about “inventing a new molecule.” They are about hitting the protected manufacturing and quality attributes required by the brand’s claimed invention.

Practical barriers that delay launches

• Matching polymorph/crystal form (if protected)
• Achieving particle size and impurity profile consistent with the claimed process and NDA specs
• Replicating dissolution/exposure curves under controlled-release or special formulation claims
• Avoiding proprietary process steps for crystallization and purification

Competitive outcome

Because many fluoroquinolone products are already widely available in multiple generics, the economic battle often shifts to:

• Price compression
• Supply chain reliability
• Contracting dynamics with wholesalers and GPOs
• Differentiation via dosage form usability (pill burden, ophthalmic delivery, etc.)

How does the fluoroquinolone market behave compared with other antibiotics?

Fluoroquinolones sit in a mature market with strong generic competition and periodic demand shifts driven by:

• Stewardship and prescribing guidelines that can be more restrictive for certain indications
• Safety label evolution (class-wide warnings that impact patient selection)
• Seasonal or outbreak-driven changes for specific infections
• Hospital formulary decisions and antimicrobial management protocols

Commercial implication for patent strategy

For most investors and licensors, the value of IP in J01MA is typically concentrated in a narrow set of live patents and in product lifecycle strategy (new delivery systems, narrow indications) rather than in broad molecule ownership.

Which geographic markets matter most for fluoroquinolones IP and exclusivity?

• United States: Orange Book, Hatch-Waxman exclusivities, and Paragraph IV litigation drive the practical timing of generic entry.
• European Union: Supplementary Protection Certificates (SPCs) and national enforcement matter; generics can leverage local manufacturing scale and patent enforcement variations.
• Other major markets: regulatory data exclusivity and local patentability standards can produce timing deviations, but most competitive dynamics are still anchored in the US/EU.

Key patent-lifecycle playbook for fluoroquinolone brands and challengers

For originators and 505(b)(2) sponsors

• Prioritize enforcement of solid-state and formulation patents tied to the commercial dosage form.
• Keep Orange Book listings current where they map to the marketed strengths and forms.
• Use litigation or licensing to prevent early generic “drop-ins” where design-around is expensive.

For generics and investors

• Evaluate infringement exposure by dosage form and strength, not the active ingredient alone.
• Focus on design-around feasibility for polymorph/formulation/process claims.
• Model launch timing around likely settlement windows rather than only hard expiry dates.

Key Takeaways

• Fluoroquinolones (ATC J01MA) are mature; most primary compound patents are expired, so the remaining patent moat is mainly secondary lifecycle IP by product and dosage form.
• Patent strength is typically strongest for solid-state (polymorph/crystal form) and tightly defined formulation claims that are hard to design around without changing regulatory or performance characteristics.
• Paragraph IV litigation is episodic and usually tied to a specific remaining Orange Book-listed patent rather than to the whole class.
• Market dynamics are dominated by generic pricing and contracting; residual branded value concentrates in specific protected delivery systems and narrow indications.

FAQs

1. What patent families most often block generic fluoroquinolone launches in the US?
   Orange Book-listed secondary patents covering polymorph/crystal form, formulation composition, controlled-release mechanics, and sometimes process routes tied to the NDA product.

2. Do fluoroquinolone method-of-use patents meaningfully affect generic entry timing?
   They can, but formulation and solid-state patents typically present the more practical infringement and design-around barriers.

3. How do settlement agreements in antibiotics affect entry dates and launch scope?
   Settlements commonly trade early entry for design-around commitments and may restrict entry to certain strengths or dosage forms with carve-outs.

4. What delivery technologies create the most patentable differentiation in J01MA?
   Controlled-release oral formats and specialized ophthalmic/otic vehicles where formulation and performance parameters are linked to claimed inventions.

5. Is SPC a major driver of fluoroquinolone exclusivity in the EU?
   SPC availability and enforcement depend on product history and national practice, but where present, SPCs can extend exclusivity beyond the base patent term.

References

1. US Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
2. European Medicines Agency. Supplementary Protection Certificate (SPC) and regulatory protection guidance. EMA.
3. US Food and Drug Administration. Drugs@FDA. FDA.